MDMB-FUBINACA

MDMB-FUBINACA is a synthetic cannabinoid that is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor and CB2 receptor with EC50 values of 0.14 nM and 0.264 nM, respectively. It was originally developed by Pfizer in 2009 as an analgesic medication, but it is now predominantly used as a designer drug.

History

MDMB-FUBINACA was first reported in 2014 and quickly gained a reputation as the most deadly synthetic cannabinoid drug sold to date. Up to 700 hospitalisations and 25 deaths were initially linked to MDMB-FUBINACA in media reports.

Pharmacology

As with all synthetic cannabinoids, the precise mode of action of MDMB-FUBINACA is not fully understood. It is known to be a potent agonist of the CB1 receptor, which is the primary binding site of tetrahydrocannabinol (THC), the main psychoactive component in cannabis.

Legal Status

MDMB-FUBINACA is illegal in most jurisdictions. It is classified as a Schedule I controlled substance in the United States and is also controlled in China.

See Also

• Synthetic cannabinoids
• Indazole
• CB1 receptor
• CB2 receptor
• Pfizer
• Designer drug

MDMB-FUBINACA Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski